InSite Vision, Inc.
Investors
Profile

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care pati... More >>

Stock Quote
INSV (Common Stock)
Symbol INSV (Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.41
Change (%) Stock is Up 0.03 (7.89%)
Volume65,200
Data as of 05/17/12 3:56 p.m. ET
Minimum 20 minute delay
Refresh quote
Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
Latest Reports
DateTitle
08/04/11
Download Documentation S-1 (Registration statement for face-amount certificate companies)


Latest Presentation
DateTitle
03/20/12
Download Documentation InSite Vision Corporate Presentation – March 2012
Get help downloading or viewing the above file types
Recent News More >>
DateTitle 
05/01/12InSite Vision Reports First Quarter 2012 Financial ResultsPrinter Friendly Version
04/23/12InSite Vision to Report First Quarter 2012 Financial Results on May 1, 2012Printer Friendly Version
03/07/12InSite Vision to Present at the 24th Annual ROTH ConferencePrinter Friendly Version
03/05/12InSite Vision Announces Date for Annual Shareholder MeetingPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.